Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 12;7(3):208.
doi: 10.3390/jof7030208.

In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale

Affiliations

In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale

Keita Sugiura et al. J Fungi (Basel). .

Abstract

To evaluate the combination effects of anti-onychomycosis drugs, the minimum inhibitory concentrations of topical (efinaconazole, luliconazole, and tavaborole) and oral (itraconazole and terbinafine) drugs for Trichophyton rubrum and Trichophyton interdigitale (8 each, with a total of 16 strains) were determined using the microdilution checkerboard technique based on the Clinical and Laboratory Standard Institute guidelines. No antagonism was observed between the topical and oral drugs against all the tested strains. Efinaconazole with terbinafine exerted a synergistic effect on 43.8% of the strains tested (7/16 strains) and efinaconazole with itraconazole on 12.5% (2/16 strains). Conversely, luliconazole showed no synergistic effect with terbinafine but was synergistically effective with itraconazole against 31.3% of the strains (5/16 strains). Tavaborole showed no synergistic effect with terbinafine and was synergistically effective with itraconazole against 18.8% of the strains (3/16 strains). The results suggest that a combination of topical and oral drugs could be a potential clinical option for onychomycosis treatment, and overall, the efinaconazole and oral drug combination would be the most advantageous among the tested combinations.

Keywords: FIC index; anti-onychomycosis drug; combination antifungal effect.

PubMed Disclaimer

Conflict of interest statement

The authors are the employees and stockholders of Kaken Pharmaceutical Co., Ltd. Kaken Pharmaceutical Co., Ltd. discovered Clenafin/Jublia, a topical onychomycosis treatment product that contains efinaconazole. Jublia is commercialized in the United States and Canada by Bausch Health Companies Inc.

Figures

Figure 1
Figure 1
Combination antifungal effect of topical drugs and oral drugs against T. rubrum and T. interdigitale (each 8 strains) (a) with terbinafine, (b) with itraconazole. Figures in the bar express number of strains observed in each combination effect.

Similar articles

Cited by

References

    1. Gupta A.K., Jain H.C., Lynde C.W., Macdonald P., Cooper E.A., Summerbell R.C. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: A multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. 2000;43:244–248. doi: 10.1067/mjd.2000.104794. - DOI - PubMed
    1. Watanabe S., Harada T., Hiruma M., Iozumi K., Katoh T., Mochizuki T., Naka W., Japan Foot Week Group Epidemiological survey of foot diseases in Japan: Results of 30,000 foot checks by dermatologists. J. Dermatol. 2010;37:397–406. doi: 10.1111/j.1346-8138.2009.00741.x. - DOI - PubMed
    1. Elewski B.E. Onychomycosis: Pathogenesis, diagnosis, and management. Clin. Microbiol. Rev. 1998;11:415–429. doi: 10.1128/CMR.11.3.415. - DOI - PMC - PubMed
    1. Baker S.J., Hui X., Maibach H.I. Progress on new therapeutics for fungal nail infections. Annu. Rep. Med. Chem. 2005;40:323–335.
    1. Gupta A.K., Konnikov N., Lynde C.W. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J. Am. Acad. Dermatol. 2001;44:479–484. doi: 10.1067/mjd.2001.110874. - DOI - PubMed

LinkOut - more resources